Globus Medical, Inc. Peer Comparison
Metric | Value | Ranking | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $11.4 Billion | 2/16 | PODD $19.7B |
GMED $11.4B |
GKOS $8.4B |
BRKR $7.6B |
INSP $5.5B |
ITGR $4.7B |
NARI $4.7B |
IRTC $3.5B |
LIVN $2.6B |
NVCR $2.4B |
NUVA $2.1B |
CNMD $2.0B |
ATEC $1.5B |
HSKA $1.3B |
OFIX $711.2M |
NVRO $216.2M |
Gross Margin | 57% | 12/16 | PODD 100% |
ATEC 100% |
NARI 87% |
INSP 85% |
GKOS 77% |
NVCR 77% |
NUVA 72% |
LIVN 71% |
IRTC 69% |
OFIX 69% |
NVRO 67% |
GMED 57% |
CNMD 57% |
BRKR 47% |
HSKA 44% |
ITGR 16% |
Profit Margin | 8% | 5/16 | PODD 21% |
CNMD 15% |
INSP 15% |
LIVN 10% |
GMED 8% |
BRKR 5% |
ITGR 5% |
NUVA 2% |
NARI -12% |
OFIX -14% |
NVRO -16% |
HSKA -16% |
NVCR -20% |
GKOS -22% |
IRTC -31% |
ATEC -83% |
EBITDA margin | 8% | 6/16 | PODD 24% |
INSP 24% |
LIVN 23% |
CNMD 21% |
NUVA 19% |
GMED 8% |
ITGR 8% |
NARI -5% |
OFIX -6% |
BRKR -9% |
NVRO -14% |
HSKA -17% |
NVCR -21% |
GKOS -26% |
IRTC -34% |
ATEC -184% |
Quarterly Revenue | $625.7 Million | 3/16 | BRKR $864.4M |
ITGR $746.3M |
GMED $625.7M |
PODD $372.6M |
LIVN $318.1M |
NUVA $317.8M |
CNMD $316.7M |
INSP $239.7M |
OFIX $196.6M |
NVCR $155.1M |
NARI $153.4M |
IRTC $147.5M |
NVRO $96.9M |
GKOS $96.7M |
HSKA $62.4M |
ATEC $48.0M |
Quarterly Earnings | $51.8 Million | 2/16 | PODD $77.5M |
GMED $51.8M |
CNMD $49.0M |
BRKR $40.9M |
ITGR $35.4M |
INSP $35.2M |
LIVN $33.0M |
NUVA $7.4M |
HSKA -$9.8M |
NVRO -$15.3M |
NARI -$18.4M |
GKOS -$21.4M |
OFIX -$27.4M |
NVCR -$30.6M |
ATEC -$39.6M |
IRTC -$46.2M |
Quarterly Free Cash Flow | $161.7 Million | 1/16 | GMED $161.7M |
ITGR $131.8M |
PODD $76.1M |
INSP $62.2M |
CNMD $47.8M |
LIVN $32.8M |
OFIX $32.1M |
IRTC $15.5M |
BRKR $5.8M |
NVRO $489,000 |
NVCR -$307,000 |
NUVA -$495,000 |
NARI -$995,000 |
GKOS -$11.0M |
HSKA -$11.0M |
ATEC -$17.1M |
Trailing 4 Quarters Revenue | $2.5 Billion | 2/16 | BRKR $3.2B |
GMED $2.5B |
ITGR $2.0B |
PODD $1.8B |
CNMD $1.3B |
LIVN $1.2B |
NUVA $1.2B |
INSP $802.8M |
OFIX $784.2M |
NVCR $577.7M |
NARI $574.5M |
IRTC $560.0M |
ATEC $470.0M |
GKOS $360.3M |
NVRO $303.0M |
HSKA $254.9M |
Trailing 4 Quarters Earnings | $91.5 Million | 5/16 | BRKR $864.4M |
ITGR $746.3M |
GMED $625.7M |
PODD $372.6M |
LIVN $318.1M |
NUVA $317.8M |
CNMD $316.7M |
INSP $239.7M |
OFIX $196.6M |
NVCR $155.1M |
NARI $153.4M |
IRTC $147.5M |
NVRO $96.9M |
GKOS $96.7M |
HSKA $62.4M |
ATEC $48.0M |
Quarterly Earnings Growth | 5094% | 1/16 | GMED 5094% |
NUVA 925% |
LIVN 550% |
CNMD 209% |
INSP 139% |
PODD 49% |
NVCR 38% |
NVRO 35% |
GKOS 30% |
ITGR 30% |
ATEC 7% |
OFIX 5% |
HSKA 2% |
BRKR -54% |
IRTC -70% |
NARI -681% |
Annual Earnings Growth | -47% | 12/16 | LIVN 737% |
INSP 593% |
PODD 215% |
CNMD 131% |
NVRO 38% |
NVCR 32% |
OFIX 19% |
BRKR 18% |
ITGR 15% |
ATEC 10% |
GKOS -16% |
GMED -47% |
NUVA -50% |
HSKA -66% |
IRTC -82% |
NARI -934% |
Quarterly Revenue Growth | 63% | 1/16 | GMED 63% |
INSP 25% |
GKOS 24% |
NVCR 22% |
NARI 21% |
IRTC 18% |
BRKR 16% |
LIVN 11% |
OFIX 7% |
ITGR 6% |
CNMD 4% |
NUVA 2% |
HSKA -4% |
NVRO -7% |
PODD -14% |
ATEC -59% |
Annual Revenue Growth | 97% | 1/16 | GMED 97% |
INSP 23% |
NARI 19% |
BRKR 16% |
NVCR 14% |
GKOS 13% |
IRTC 13% |
PODD 12% |
LIVN 6% |
ITGR 6% |
OFIX 5% |
NUVA 4% |
CNMD 2% |
ATEC 0% |
HSKA -5% |
NVRO -30% |
Cash On Hand | $622.8 Million | 2/16 | PODD $902.6M |
GMED $622.8M |
IRTC $519.5M |
LIVN $346.4M |
INSP $150.2M |
BRKR $148.1M |
HSKA $125.2M |
GKOS $100.1M |
ATEC $81.0M |
NUVA $80.7M |
NVRO $72.0M |
NARI $41.1M |
CNMD $38.5M |
ITGR $35.6M |
OFIX $30.1M |
NVCR -$0 |
Short Term Debt | $11.0 Million | 9/16 | NUVA $360.8M |
NVCR $86.4M |
PODD $42.0M |
NVRO $37.9M |
BRKR $32.8M |
LIVN $22.0M |
IRTC $15.5M |
ITGR $13.9M |
GMED $11.0M |
ATEC $8.8M |
OFIX $7.0M |
HSKA $4.0M |
NARI $1.6M |
CNMD $717,000 |
GKOS -$0 |
INSP -$0 |
Long Term Debt | $523.5 Million | 9/16 | BRKR $2.3B |
PODD $1.4B |
ITGR $1.2B |
CNMD $940.1M |
IRTC $719.8M |
LIVN $604.3M |
ATEC $555.1M |
NUVA $545.4M |
GMED $523.5M |
NVRO $208.7M |
GKOS $157.1M |
OFIX $130.2M |
HSKA $105.4M |
NARI $31.1M |
INSP $30.0M |
NVCR $0 |
PE | 124.88 | 1/16 | GMED 124.88 |
LIVN 109.31 |
INSP 102.92 |
NUVA 73.28 |
PODD 46.76 |
ITGR 41.65 |
BRKR 24.88 |
CNMD 14.81 |
GKOS -1.00 |
NVCR -1.00 |
NVRO -1.00 |
IRTC -1.00 |
HSKA -1.00 |
OFIX -1.00 |
ATEC -1.00 |
NARI -1.00 |
PS | 4.61 | 7/16 | GKOS 23.44 |
PODD 10.86 |
NARI 8.15 |
INSP 6.86 |
IRTC 6.27 |
HSKA 5.14 |
GMED 4.61 |
NVCR 4.21 |
ATEC 3.24 |
ITGR 2.35 |
BRKR 2.34 |
LIVN 2.09 |
NUVA 1.70 |
CNMD 1.51 |
OFIX 0.91 |
NVRO 0.71 |
PB | 2.81 | 9/16 | IRTC 48.89 |
PODD 17.60 |
GKOS 12.64 |
NARI 10.77 |
INSP 7.98 |
BRKR 4.12 |
HSKA 3.14 |
ITGR 2.92 |
GMED 2.81 |
NUVA 2.34 |
CNMD 2.09 |
LIVN 1.98 |
OFIX 1.35 |
NVRO 0.79 |
NVCR 0.00 |
ATEC 0.00 |
PC | 18.35 | 11/16 | ITGR 132.95 |
NARI 113.78 |
GKOS 84.35 |
BRKR 51.22 |
CNMD 50.71 |
INSP 36.68 |
NUVA 25.83 |
OFIX 23.66 |
PODD 21.80 |
ATEC 18.80 |
GMED 18.35 |
HSKA 10.46 |
LIVN 7.47 |
IRTC 6.75 |
NVRO 3.00 |
NVCR -1.00 |
Liabilities to Equity | 0.25 | 14/16 | IRTC 11.68 |
NVCR 2.39 |
BRKR 2.34 |
PODD 1.71 |
CNMD 1.48 |
NUVA 1.34 |
NVRO 1.18 |
ITGR 0.95 |
LIVN 0.93 |
OFIX 0.65 |
NARI 0.60 |
HSKA 0.42 |
GKOS 0.39 |
GMED 0.25 |
INSP 0.17 |
ATEC 0.00 |
ROA | 0.02 | 6/16 | PODD 14% | INSP 7% | CNMD 6% | BRKR 5% | ITGR 4% | GMED 2% | LIVN 1% | NUVA 1% | HSKA -3% | NVRO -10% | NARI -11% | OFIX -14% | GKOS -16% | IRTC -17% | ATEC -24% | NVCR -100% |
ROE | 0.02 | 8/16 | ATEC 13059% |
PODD 38% |
BRKR 17% |
CNMD 14% |
INSP 8% |
ITGR 7% |
NUVA 3% |
GMED 2% |
LIVN 2% |
HSKA -5% |
NARI -18% |
GKOS -22% |
NVRO -22% |
OFIX -23% |
NVCR -42% |
IRTC -210% |
Current Ratio | 5.00 | 2/16 | INSP 6.81 |
GMED 5.00 |
GKOS 3.59 |
HSKA 3.39 |
NARI 2.66 |
OFIX 2.54 |
LIVN 2.08 |
ITGR 2.05 |
NVRO 1.85 |
NUVA 1.75 |
CNMD 1.67 |
PODD 1.59 |
BRKR 1.43 |
IRTC 1.09 |
ATEC 1.00 |
NVCR 0.00 |
Quick Ratio | 0.68 | 5/16 | GMED 124.88 |
LIVN 109.31 |
INSP 102.92 |
NUVA 73.28 |
PODD 46.76 |
ITGR 41.65 |
BRKR 24.88 |
CNMD 14.81 |
GKOS -1.00 |
NVCR -1.00 |
NVRO -1.00 |
IRTC -1.00 |
HSKA -1.00 |
OFIX -1.00 |
ATEC -1.00 |
NARI -1.00 |
Long Term Debt to Equity | 0.13 | 12/16 | IRTC} 10.03 |
BRKR} 1.24 |
PODD} 1.21 |
CNMD} 1.01 |
NVRO} 0.76 |
ITGR} 0.71 |
NUVA} 0.61 |
LIVN} 0.46 |
HSKA} 0.25 |
OFIX} 0.25 |
GKOS} 0.24 |
GMED} 0.13 |
NARI} 0.07 |
INSP} 0.04 |
NVCR} 0.00 |
ATEC} -407.54 |
Debt to Equity | 0.13 | 13/16 | IRTC 10.25 |
BRKR 1.26 |
PODD 1.25 |
NUVA 1.02 |
CNMD 1.01 |
NVRO 0.90 |
ITGR 0.72 |
LIVN 0.48 |
HSKA 0.26 |
OFIX 0.26 |
GKOS 0.24 |
NVCR 0.24 |
GMED 0.13 |
NARI 0.08 |
INSP 0.04 |
ATEC -413.99 |
Burn Rate | -22.13 | 14/16 | HSKA 8.35 |
IRTC 6.59 |
GKOS 3.62 |
BRKR 2.56 |
ITGR 2.48 |
NVRO 2.17 |
NARI 2.06 |
ATEC 1.26 |
OFIX 0.88 |
NUVA 0.77 |
NVCR 0.00 |
CNMD -3.43 |
INSP -4.41 |
GMED -22.13 |
PODD -70.80 |
LIVN -105.16 |
Cash to Cap | 0.05 | 5/16 | NVRO 0.33 |
IRTC 0.15 |
LIVN 0.13 |
HSKA 0.10 |
GMED 0.05 |
PODD 0.05 |
ATEC 0.05 |
NUVA 0.04 |
OFIX 0.04 |
INSP 0.03 |
BRKR 0.02 |
CNMD 0.02 |
GKOS 0.01 |
ITGR 0.01 |
NARI 0.01 |
NVCR 0.00 |
CCR | 3.12 | 2/16 | ITGR 3.72 |
GMED 3.12 |
INSP 1.76 |
HSKA 1.13 |
LIVN 1.00 |
PODD 0.98 |
CNMD 0.98 |
GKOS 0.52 |
ATEC 0.43 |
BRKR 0.14 |
NARI 0.05 |
NVCR 0.01 |
NVRO -0.03 |
NUVA -0.07 |
IRTC -0.34 |
OFIX -1.17 |
EV to EBITDA | 235.78 | 1/16 | GMED} 235.78 |
PODD} 229.01 |
ITGR} 101.10 |
INSP} 94.92 |
NUVA} 47.54 |
CNMD} 43.42 |
LIVN} 39.06 |
ATEC} -22.68 |
NVRO} -28.18 |
OFIX} -66.11 |
IRTC} -74.04 |
NVCR} -78.48 |
HSKA} -124.13 |
BRKR} -126.60 |
GKOS} -344.85 |
NARI} -648.07 |
EV to Revenue | 4.58 | 7/16 | GKOS 23.60 |
PODD 11.13 |
NARI 8.13 |
INSP 6.71 |
IRTC 6.65 |
HSKA 5.08 |
GMED 4.58 |
NVCR 4.36 |
ATEC 4.27 |
BRKR 3.00 |
ITGR 2.92 |
NUVA 2.37 |
LIVN 2.31 |
CNMD 2.21 |
NVRO 1.29 |
OFIX 1.04 |